



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (51) International Patent Classification⁴ : A61K 9/16, 9/20, 31/19 | A1 | (11) International Publication Number: WO 89/ 02266 (43) International Publication Date: 23 March 1989 (23.03.89) |
| (21) International Application Number: PCT/US88/02945 (22) International Filing Date: 24 August 1988 (24.08.88) (31) Priority Application Number: 097,850 (32) Priority Date: 17 September 1987 (17.09.87) (33) Priority Country: US (71) Applicant: MALLINCKRODT, INC. [US/US]; 675 McDonnell Boulevard, St. Louis, MO 63134 (US). (72) Inventor: DENTON, Larry, E. ; 16 Bliss Terrace, Collinsville, IL 62234 (US). (74) Agent: TARTER, Stanley, M.; Rogers, Howell, Moore & Haferkamp, 7777 Bonhomme Avenue, Suite 1700, St. Louis, MO 63107 (US). | | (81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent). Published <i>With international search report</i> <i>With amended claims</i> |
| (54) Title: A FREE-FLOWING GRANULAR COMPOSITION CONTAINING IBUPROFEN AND A METHOD FOR ITS PREPARATION (57) Abstract A granular composition containing 2-(4-isobutylphenyl)propionic acid (ibuprofen) as an active anti-inflammatory pharmaceutical ingredient as a major component, together with carboxymethylcellulose, a lubricant and water as minor components, is disclosed. Particles of ibuprofen and carboxymethylcellulose are both fluidized and coated with an aqueous dispersion of a starch binder. After being dried to a moisture level of about 1-5 % and blended with a lubricant and additional carboxymethylcellulose, the resulting granules can be directly molded into a pharmaceutically acceptable tablet having high hardness, short disintegration time and fast dissolution rate. | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|------------------------------|----|------------------------------------------|----|--------------------------|
| AT | Austria | FR | France | ML | Mali |
| AU | Australia | GA | Gabon | MR | Mauritania |
| BB | Barbados | GB | United Kingdom | MW | Malawi |
| BE | Belgium | HU | Hungary | NL | Netherlands |
| BG | Bulgaria | IT | Italy | NO | Norway |
| BJ | Benin | JP | Japan | RO | Romania |
| BR | Brazil | KP | Democratic People's Republic of Korea | SD | Sudan |
| CF | Central African Republic | KR | Republic of Korea | SE | Sweden |
| CG | Congo | LI | Liechtenstein | SN | Senegal |
| CH | Switzerland | LK | Sri Lanka | SU | Soviet Union |
| CM | Cameroon | LU | Luxembourg | TD | Chad |
| DE | Germany, Federal Republic of | MC | Monaco | TG | Togo |
| DK | Denmark | MG | Madagascar | US | United States of America |
| FI | Finland | | | | |

-1-

A free-flowing granular composition containing ibuprofen and a method for its preparation.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to new and useful tabletable pharmaceutical compositions and methods of making the same. More particularly, the present invention relates to new and useful granular compositions containing ibuprofen which are eminently suitable for forming into tablets and methods for preparing such compositions using a fluidized bed apparatus.

2. Description of Prior Art

Ibuprofen, the generic name for 2-(4-isobutylphenyl)propionic acid, is a well known anti-inflammatory drug and is disclosed in U.S. Patents 3,228,831 and 3,385,886.

Normally, ibuprofen is formulated for sale to the consumer in the form of compressed tablets or capsules. U.S. Patent 4,609,675 discloses a method of preparing a pharmaceutical ibuprofen-containing granulate composition suitable for preparing tablets of relatively high dosage. This is accomplished by dry mixing ibuprofen with croscarmellose sodium NF

(cross-linked sodium carboxymethylcellulose) in certain relative amounts, passing the resulting mixture through a roller compactor or slugging the composition and thereafter applying a size to the resulting compacted or slugged product.

Acetaminophen, the generic name for N-acetyl-p-aminophenol, is a well known analgesic drug and is disclosed in U.S. Patent 2,998,450.

U.S. Patent 4,661,521 discloses a method of preparing a pharmaceutical acetaminophen-containing granulate composition suitable for shaping into tablets. This is accomplished by using a fluid bed granulator-dryer involving spraying an aqueous slurry of a portion of a pregelatinized starch onto a fluidized composition of acetaminophen and thereafter drying the same. A lubricant may be added during or after drying.

Ibuprofen-containing granules having good compressibility properties to form tablets is a desideratum of long standing. Heretofore, when granules of ibuprofen are compressed to insure good crumbling resistance, the dissolution rate of the tablets is slower than desired.

SUMMARY OF THE INVENTION

Briefly, the present invention provides a new free-flowing pharmaceutical dry granules containing ibuprofen. The granules are suitable for directly shaping into tablets having excellent compressibility properties such that tablets compressed from the granules have good resistance to crumbling without significant sacrifice of the dissolution rate of the tablet.

The present invention also provides a method of preparing a free-flowing particulate composition capable of being directly formed into a tablet having high hardness, short disintegration time, and fast dissolution rate without being unacceptably friable.

The composition comprises as components

thereof:

- a) the pharmaceutically active ingredient of ibuprofen in an amount of about 50 to 85 weight percent based on the total weight of the final composition, 5
- b) the pharmaceutically acceptable cellulosic disintegrant of an internally cross-linked alkali (sodium) carboxymethylcellulose in an effective amount of about 1-5 weight percent. Additionally, a pharmaceutically acceptable pregelatinized starch of about 10-25 weight percent and a microcrystalline cellulose of about 6-18 weight percent may be included along with carboxymethylcellulose as binders and disintegrants. The amount of 10 disintegrants is sufficient to impart excellent dissolution and disintegration characteristics to tablets made therefrom,
- c) optionally, the pharmaceutically acceptable binder of povidone in an amount of about 20 0.1-3.0 weight percent sufficient to impart suitable binding properties to tablets made from the composition,
- d) a pharmaceutically acceptable lubricant in an effective amount of about 0.1-3.0 weight percent for imparting sufficient mold release properties to tablets made from the composition, and 25
- e) water in an effective amount of about 1.0-5.0 weight percent.

The dosage of the ibuprofen active ingredient will normally range from about 100 to about 300 mg per tablet made from the composition of the present invention. 30

It is important that the arrangement of the ingredients of the compositions of the resulting granules be achieved by a fluid bed granulation-drying technique involving the steps of: 35

- a) charging the ibuprofen and a portion of the cellulosic disintegrant to a fluid bed granulator-dryer,

b) fluidizing the ibuprofen and cellulose disintegrant until thoroughly blended,

c) dispersing pregelatinized starch and water with a high sheer mixer to form a dispersion
5 having from about 5 to about 15 weight percent solids,

d) spraying the starch dispersion onto the fluidized bed of active ingredient and cellulose disintegrant at a rate sufficient to maintain the
10 fluidized bed moisture between 5 to about 20 percent by weight,

e) continuing drying after all the dispersion has been sprayed to reach a bed moisture of about 5 percent by weight or less,

15 f) stopping the fluidization,

g) transferring the dried product of the fluidization to a blender,

h) adding an lubricant to the blender, and

i) blending the lubricant onto the fluid-
20 ized composition.

DETAILED DESCRIPTION OF THE INVENTION

The ibuprofen component is preferably provided in a powder or other finely divided form. The ibuprofen powder should be of high purity of greater
25 than 99%. It has been found that when more than 30% by weight of the ibuprofen powder is larger than 60 mesh (U.S. Standard Sieve), then the compressibility of the granules is adversely affected. For use in the present invention preferably all of the ibuprofen
30 powder should pass through a .60 mesh screen, more preferably 95% will pass through an 100 mesh screen. The particle size of the ibuprofen powder is about 15-60 microns.

The internally cross-linked alkalai
35 carboxymethylcellulose component of the directly tabletable composition of the present invention may be obtained from any well known manufacturer such as, for example, FMC Corporation of Philadelphia, Pennsylvania. Sodium carboxymethylcellulose is a cel-

lulose ether produced by reacting alkali cellulose with sodium monochloroacetate under rigidly controlled conditions. This cellulosic material in solid pharmaceutical compositions aids in the dissolution rates and disintegration characteristics and must meet all of the NF requirements for such material.

The pregelatinized starch may be obtained from any well known manufacturer such as, for example, the National Starch Corporation. Pregelatinized starches useful in the present invention should meet all the NF requirements for such starches.

Povidone may be included as an optionally additional binder and is a polymer of vinylpyrrolidone and is produced commercially as a series of products having mean molecular weights ranging from about 10,000 to 700,000. Povidone is also readily available from various manufacturers as a pharmaceutical excipient.

The lubricant component may be any suitable pharmaceutically acceptable lubricant, which may be, e.g., hydrophilic or hydrophobic. This component is present in a lubricating amount at least sufficient to impart mold release properties to tablets formed from the compositions and preferably insufficient to increase disintegration and dissolution time of such tablets, and preferably insufficient to decrease the hardness of tablets formed from compositions of this invention containing lower lubricating amounts of the same lubricant.

Suitable lubricants for use as the lubricating component include, for example, stearic acid, metal stearates, such as sodium, calcium, magnesium and zinc stearate etc., sodium lauryl sulfate, polyethylene glycol, hydrogenated vegetable oils, talc and compressible mixtures of two or more such materials. Stearic acid and calcium stearate, singly or in combination, are preferred.

In general the lubricant may be present in

an amount from about 0.1 to about 3.0 percent, more preferably from about 0.5 to 1.5 percent, and most preferably about 1 percent, based on the total dry weight of the composition.

5 The composition also includes water in an amount effective for aid in direct tablet formation. Such an effective amount is generally found to be between about 1.0 to 5.0 percent based on the total weight of the composition, preferably from about 2.3
10 to 3.3 percent on the same basis.

 To increase the shelf life of the tablets, the composition may also contain an effective amount of a preservative. Suitable preservatives include methyl paraben which is the methyl ester of
15 parahydroxybenzoic acid and propyl paraben which is the propyl ester of parahydroxybenzoic acid. Both of these esters are known substances for preventing microbial contamination. While the preservatives may be added during any stage in the building of the
20 granules of the present invention, it is preferred that any preservative be added during the spraying step.

 Optionally, the composition may further include a pharmaceutically acceptable compressibility-promoting binder as an additional binding agent in
25 the amount effective for increasing the obtainable hardness of tablets formed from the composition. Materials suitable for use as the optionally included binding agents include, for example, starch paste,
30 polyvinylpyrrolidone, hydroxypropylmethylcellulose, hydroxypropylcellulose, gelatin, microcrystalline cellulose, natural gums, e.g., gum acacia, gum tragacanth, etc., sucrose, mannitol, ethylcellulose, synthetic polymer binders, used in the industry and
35 compatible mixtures of two or more of the materials. Polyvinylpyrrolidone (PVP) is preferred (more preferably PVP®K-90). In general, such an effective amount of optional binder is from about 0.5 or less to about 2.5 or more dry weight percent, preferably

not more than 1.5, more preferably about 1.0 dry weight percent of the composition.

A preferred embodiment of the present invention includes the following components in the amounts indicated.

TABLE 1

| | <u>Component</u> | <u>Approximate Amount</u> |
|----|----------------------------------|---------------------------|
| | Active | 50-85 |
| | carboxymethylcellulose | 1-5 |
| 10 | Additional binders/disintegrants | 10-45 |
| | Lubricant | 0.1-3.0 |

The amounts shown in Table 1 are in parts per 100 parts on a dry basis of the granular composition.

The best embodiment composition of the invention contemplated at the time of executing this patent application is as follows, wherein the amounts given are in parts per 100 parts by weight on a dry basis of the granular composition.

TABLE 2

| | <u>Component</u> | <u>Approximate Amount</u> |
|----|-------------------------------|---------------------------|
| | Ibuprofen | 63.0 |
| | Na carboxymethyl cellulose | 3.0 |
| 25 | Pregelatinized starch | 17.4 |
| | Microcrystalline cellulose | 15.0 |
| | Lubricant | 1.0 |
| | Povidone | 0.5 |
| 30 | Preservative | 0.1 |

In general, the just mentioned composition can be repeatedly formed into tablets having a hardness of 5 kp or more and having a disintegration rate of 5 minutes or less.

In use, the granular compositions of the present invention advantageously may be built to include other active ingredients and/or other excipients. The additional substances may be added either prior to compositing the components to form

the granular composition or after the composition is formed (e.g., by dry blending the built granules with such ingredients). Thereafter, the composition may be directly compressed into tablets having

5 eminently suitable values of hardness and disintegration rates for a variety of end use applications including the formation of tablets and capsules.

The compositions of the present invention are preferably made by the method mentioned above,

10 which includes the use of a fluidized bed granulator-dryer. A suitable sized fluidized bed granulator-dryer is charged with ibuprofen and a portion of the cellulosic disintegrant. The amount of cellulosic material added is from about 1 to about 5

15 percent by weight based on the total weight of the composition. Preferably, about 1.5 percent of the cellulosic material is charged to the fluidized bed. The substances added to the granulator-dryer initially are fluidized until they are thoroughly blended..

20 A second portion of the cellulosics is dispersed in water to yield a slurry of between about 5 and about 15 weight percent solids, using a high sheer mixer. Other components, if desired, may be added either to the dry blend or to the slurry, as needed. The re-

25 sulting dispersion is then sprayed onto the fluidized bed of ibuprofen and the cellulosic material at a rate sufficient to maintain a bed moisture between about 5 and 20 weight percent and preferably between about 10 and about 16 percent by weight. After complete addition of the dispersion to the fluid bed,

30 the fluidization is continued until the bed moisture has been reduced to about 2 to about 5 percent. The fluidization is then halted. After the fluidization is terminated, the material is sized to the desired

35 proportionate dimensions by using suitable equipment such as a Glatt Quick Sieve or Stoke's Granulator. A lubricant is blended with the suitably sized granules using a suitable blending device, such as a double-cone blender which is preferred.

The fluidized bed granulator-dryer may be operated under the following conditions: a stream of heated air is introduced from the bottom of the fluid bed at a sufficient velocity and force to fluidize the powder bed of ibuprofen and cellulosic disintegrant and at a temperature sufficient to heat the powder bed to between about 20°C and about 50°C. The air velocity, inlet air temperature and the powder bed temperature are dependent on the batch size, dew point of air, and spray rate of the binder solution during the granulation phase and therefore are adjusted accordingly. The particle size of the bed material is influenced by the atomization pressure used to spray the granulating dispersion, as well as by the moisture level of the fluid bed during the granulation stage. By adjusting operating parameters, the desired particle size and size distribution of the granules can be obtained. If needed, further sizing of the dry granules to obtain a narrow particle size distribution may be achieved by using a Glatt Quick Sieve or other suitable sizing equipment. The built granules preferably will have a particle size of about 140-225 microns.

The term "direct tableting" and terms of like import, as used herein, means that the composition can be formed into a tablet using conventional tablet-forming apparatus and processes without the need for addition of any adjuvant material to the composition. As used herein the term "kp" means kilo ponds, a well known unit of force for expressing hardness or crushing strength of pharmaceutical tablets, when such hardness is determined on a Schleuniger Tablet Hardness Tester.

The following examples and tables illustrate the invention. As used herein, the following terms have the meanings indicated:

a) "Disintegration time" means the time measured using the disintegration time test method set forth in U.S. Pharmacopeia (hereinafter "USP")

XXI for uncoated tablets except that the disks are not employed;

b) "Dissolution time" means the time measured using the dissolution time test method set forth in USP XXI for ibuprofen tablets;

c) "Hardness" means the hardness measured on a Schleuniger Tablet Hardness Tester;

d) "Maximum hardness" means the maximum hardness in which the tablets are substantially free of lamination;

e) "Friability" means the friability measured on a Roche Friabulator for 20 tablets and 100 revolutions.

Unless otherwise indicated, all tablet hardness values are averages for 10 tablets and all tablet weights are averages obtained by weighing 20 tablets as a whole and then dividing by 20. Further, unless otherwise indicated, tablet disintegration times were measured for tablets having about 9 kp hardness.

EXAMPLE 1

Using the procedure described above, a directly tabletable granular composition was prepared in a fluid bed granulator-dryer (Aeromatic, Inc. Model STREA-1) from the following components given on a dry weight percent basis.

TABLE 3

| | <u>Components</u> | <u>Approximate Amounts, %</u> |
|----|----------------------------|-------------------------------|
| | Ibuprofen | 55.5 |
| 30 | Povidone K-90 USP | 0.5 |
| | Pregelatinized Starch USP | 3.5 |
| | Na carboxymethylcellulose | 3.0 |
| | Corn starch | 18.0 |
| | Calcium hydrogen phosphate | 19.0 |
| 35 | Magnesium stearate | 0.5 |

The batch size exclusive of added water was 1.0 kg. The composition was dried to a final moisture content of 2.4 percent.

The granular composition was directly

formed into tablets of 9.5 mm diameter, which had the physical properties as set forth in Table 4 below.

TABLE 4

| | <u>Properties</u> | <u>Values</u> |
|----|-------------------------------|----------------|
| 5 | Tablet weight | 361 mg |
| | Tablet hardness | 12.8 kp |
| | Maximum hardness | 18.3 kp |
| | Tablet disintegration time | 2 min. 20 sec. |
| | Tablet dissolution time(T 80) | <10 min |
| 10 | Tablet friability | 0.4 % |

EXAMPLE 2

Using the procedure described above, a directly tabletable granular composition was prepared as in Example 1 from the following components given on a dry weight percent basis.

TABLE 5

| | <u>Components</u> | <u>Approximate Amounts</u> |
|----|----------------------------|----------------------------|
| | Ibuprofen | 55.5 |
| | Pregelatinized starch USP | 18.0 |
| 20 | Calcium hydrogen phosphate | 24.0 |
| | Na carboxymethylcellulose | 1.8 |
| | Magnesium stearate | 0.5 |
| | Methyl paraben | 0.16 |
| | Propyl paraben | 0.04 |

25 The batch size exclusive of added water was 1.0 kg. The composition was dried to a final moisture content of 3.1 percent.

The granular composition was directly formed into tablets of 9.5 mm diameter, which had the physical properties set forth in Table 6 below.

TABLE 6

| | <u>Properties</u> | <u>Values</u> |
|----|--------------------------------|---------------|
| | Tablet weight | 364 mg |
| | Tablet hardness | 11.8 kp |
| 35 | Maximum hardness | 16.3 kp |
| | Tablet disintegration time | 2.8-3.2 min |
| | Tablet dissolution time (T 80) | <10 min |
| | Tablet friability | 0.4 % |

12

EXAMPLE 3

Using the procedure described above, a directly tabletable granular composition was prepared in a fluidized bed granulator-dryer (Glatt Air
5 Technique, Inc.) from the following components given on a dry weight percent basis.

TABLE 7Charge to Fluid Bed

| | | |
|----|----------------------------|-------|
| | Ibuprofen | 63 |
| 10 | Pregelatinized starch NF | 13.88 |
| | Microcrystalline cellulose | 10 |
| | Na carboxymethylcellulose | 1.5 |

Dispersion

| | | |
|----|--------------------------|------|
| | Methyl paraben | 0.1 |
| 15 | Propyl paraben | 0.02 |
| | Povidone (PVP K-90) USP | 0.5 |
| | Pregelatinized starch NF | 3.5 |

Charge to Blender

| | | |
|----|----------------------------|-----|
| | Stearic acid NF | 0.5 |
| 20 | Ca stearate NF | 0.5 |
| | Na carboxymethylcellulose | 1.5 |
| | Microcrystalline cellulose | 5.0 |

The batch size exclusive of added water was 452.1 kg. The composition was dried to a final
25 moisture content of 2.8 percent and had a density of 0.51 g/cc. The granular composition was sized to the following particle size distribution using a Glatt Quick Sieve.

TABLE 8

| | | |
|----|-------------|-----------------------|
| 30 | <u>Mesh</u> | <u>Cum % Retained</u> |
| | +20 | 7 |
| | +60 | 49 |
| | +100 | 69 |
| | +200 | 89 |
| 35 | -200 | 100 |

The granular composition was directly formed into tablets of 10.3 mm diameter, which had the tablet physical properties as setforth in Table 9 below.

TABLE 9

| | <u>Properties</u> | <u>Values</u> |
|---|--------------------------------|---------------|
| | Tablet weight | 324 mg |
| | Tablet hardness | 6.6 kp |
| 5 | Maximum hardness | 6.6 kp |
| | Tablet disintegration time | 2 min |
| | Tablet dissolution time (T 80) | <10 min |
| | Tablet friability | 0.5 % |

EXAMPLE 4

10 In this example the same ingredients in the same proportions as used to form the tablets of Example 3 were physically mixed together without being subjected to the process of the present invention using the fluidized bed technique. It was found that
15 the physical blend could not be tableted because of the poor flow characteristics.

EXAMPLE 5

 In this example the procedure described in Example IV of U.S. Patent 4,661,521 was followed except that instead of using acetaminophen as the
20 active ingredient, ibuprofen was used. It was found that tablets made from the ibuprofen-containing granules had inferior dissolution and disintegration characteristics as compared to tablets made from the
25 acetaminophen-containing granules. Furthermore, tablet lubrication is very poor with the ibuprofen granules.

 It is understood that the foregoing detailed description is given merely by way of illustration and that many modifications may be made
30 therein without departing from the spirit or scope of the present invention.

What Is Claimed Is:

1.

A free-flowing particulate ibuprofen-containing granular composition capable of being directly molded into a pharmaceutically acceptable tablet having high hardness, short disintegration
5 time and fast dissolution rate comprising:

(a) from about 50 to about 85 percent, based on the dry weight of the composition, of ibuprofen;

(b) from about 1 to about 5 percent, based
10 on the dry weight of the composition, of an internally cross-linked alkali carboxymethylcellulose;

(c) a pharmaceutically acceptable lubricant in an amount of at least sufficient to impart effective mold release properties to the tablet;

(d) cellulose and starch binders and
15 disintegrants; and

(e) water therefor,

said composition having been prepared in a fluidized bed granulator-dryer by process which comprised spraying an aqueous dispersion of a starch
20 binder onto a fluidized powder comprising ibuprofen and a portion of the said carboxymethylcellulose, drying the resulting granules to a moisture level of from about 1 to about 5 percent based on the total
25 weight of the composition; and thereafter blending a lubricant and the remaining portion of the said carboxymethylcellulose with the dry granules.

2.

A tablet shaped from the composition of Claim 1.

3.

A free-flowing particulate ibuprofen-containing granular composition capable of being directly molded into a pharmaceutically acceptable tablet having high hardness, short
5 disintegration time and fast dissolution rate comprising as components thereof:

(a) from about 50 to about 85 percent, based on the dry weight of the composition, of ibuprofen;

10 (b) from about 1 to about 5 percent based on the dry weight of the composition, of an internally cross-linked alkali carboxymethylcellulose;

(c) a pharmaceutically acceptable lubricant in an amount of at least sufficient to impart
15 effective mold release properties to the tablet;

(d) cellulose and starch binders and disintegrants; and

(e) water,

said composition having been prepared in a
20 fluidized bed granulator-dryer by a process which comprises spraying an aqueous dispersion of a starch binder onto a fluidized powder comprising ibuprofen and a portion of the said carboxymethylcellulose, drying the resulting granules to a moisture level of
25 from about 1 to about 5 percent based on the total weight of the composition; and thereafter blending a lubricant and the remaining portion of the said carboxymethylcellulose with the dry granules.

4.

A tablet shaped from the composition of Claim 3.

5.

The composition of Claim 3 wherein the blending is carried out using a double-cone blender.

6.

The composition of Claim 2 wherein the lubricant is stearic acid and comprises about 0.1 to 3.0 percent based on the dry weight of the composition.

7.

The composition of Claim 3 wherein the lubricant is calcium stearate and comprises about 0.1 to 3.0 percent based on the dry weight of the composition.

8.

The composition of Claim 7 wherein the aqueous spray contains a second pharmaceutically acceptable compressibility-promoting binder in an amount effective for further increasing the obtain-
5 able hardness of tablets formed from such composition.

9.

The composition of Claim 8 wherein the second binder is povidone.

10.

The composition of Claim 3 wherein the initially fluidized powder contains a second pharmaceutically acceptable compressibility-promoting binder in an amount effective for further increasing
5 the hardness of tablets formed from such composition.

11.

The composition of Claim 10 wherein the second binder is pregelatinized starch.

12.

A method of building free-flowing particulate ibuprofen-containing granules capable of being directly molded into a pharmaceutically acceptable tablet having high hardness, short
5 disintegration time, and fast dissolution rate comprising:

(a) fluidizing a finely divided powder of ibuprofen and an internally cross-linked alkali carboxymethylcellulose, each component having a
10 particle size of about 15 to about 60 microns;

(b) during the fluidization, spraying the fluidized powder with an aqueous dispersion of a pharmaceutically acceptable compressibility-promoting binder in an amount effective for increasing the
15 obtainable hardness of tablets made from the resulting composition;

(c) ceasing the spraying;

(d) continuing the fluidization until the thus-built granules have a moisture content of about

17.

- 20 2.0 to 5.0 weight percent water based on the total
weight of the composition;
- (e) ceasing the fluidization; and
- (f) blending the dried granules with a
pharmaceutically acceptable lubricant in an amount at
25 least sufficient to impart effective mold release
properties to tablets made from the resulting gran-
ules, and with additional carboxymethylcellulose
whereby free-flowing granules having a particle size
of about 140-225 microns are produced and being
30 capable of being directly formed into pharmaceutical-
ly acceptable tablets.

13.

The process of Claim 12 wherein the blend-
ing is carried out using a double-cone blender.

14.

The process of Claim 12 wherein the lub-
ricant is stearic acid and comprises about 0.1 to 3.0
percent based on the dry weight of the granules.

15.

The process of Claim 12 wherein the lub-
ricant is calcium stearate and comprises about 0.1
to 3.0 percent based on the dry weight of the gran-
ules.

16.

- The process of Claim 12 wherein the aqueous
spray dispersion contains a second pharmaceutically
acceptable compressibility-promoting binder in an
amount effective for further increasing the obtain-
5 able hardness of tablets formed from the granules.

17.

The process of Claim 16 wherein the second
binder is povidone.

18.

- The process of Claim 12 wherein both the
initially fluidized powder contains a second pharm-
aceutically acceptable compressibility-promoting
binder in an amount effective for increasing the
5 hardness of tablets formed from the granules.

19.

The process of Claim 18 wherein the second binder is pregelatinized starch.

20.

The process of Claim 12 wherein a preservative is added during the spraying step in an amount sufficient to minimize microbial contamination of tablets made from the granules.

21.

The process of Claim 20 wherein the preservative is a lower alkyl ester of parahydroxybenzoic acid.

22.

The process of Claim 21 wherein the alkyl moiety of the preservative is C_1-C_5 alkyl.

23.

A method of building a free-flowing particulate ibuprofen-containing granules capable of being directly molded into a pharmaceutically acceptable tablet having high hardness, short disintegration time, and fast dissolution rate comprising:

5 (a) fluidizing a dry finely divided powder of ibuprofen together with a pharmaceutically acceptable binder composed of a mixture of internally cross-linked sodium carboxymethylcellulose,
10 pregelatinized starch and microcrystalline cellulose, each ingredient of which having a particle size of about 15 to about 60 microns.

(b) during the fluidization, spraying the fluidized powder with an aqueous dispersion containing a pharmaceutically acceptable binder composed of a mixture of pregelatinized starch and povidone
15 and a lower alkyl ester of parahydroxybenzoic acid as a pharmaceutically acceptable preservative;

(c) ceasing the spraying;

20 (d) continuing the fluidization until the intermediate built granules have a moisture content of about 2.0 to about 5.0 weight percent water based on the total weight of the composition;

(e) ceasing the fluidization;

25 (f) blending the intermediate built granules with a lubricant, additional internally cross-linked sodium carboxymethylcellulose and microcrystalline cellulose as a mixture of binders;

(g) the binders present in the initially
30 fluidized powder and the aqueous dispersion and added during blending being present in an amount effective for increasing the obtainable hardness of tablets molded from the ultimate granules;

(h) the lubricant being present in an
35 amount sufficient to impart effective mold release properties to tablets molded from the ultimate granules;

(i) the preservative being present in an
40 amount sufficient to minimize microbial contamination of tablets molded from the ultimate granules;

whereby free-flowing granules having a
particle size of about 140-225 microns are built and
being capable of directly molded into pharmaceutical-
ly acceptable tablets with an ibuprofen dosage of
45 about 100 to about 300 mg.

24.

The process of Claim 23 wherein the in-
ternally cross-linked sodium carboxymethylcellulose
composes about 3 weight percent of the ultimate gran-
ules and having been incorporated in the initially
5 fluidized powder and in the composition added during
blending in approximately equal amounts.

25.

The process of Claim 24, wherein the ulti-
mate granules on a dry basis comprises about 63%
ibuprofen, about 17% pregelatinized starch, about 15%
microcrystalline cellulose, 3% internally
5 cross-linked sodium carboxymethylcellulose, about 1%
lubricant, about 0.5% povidone and about 0.1% lower
alkyl ester of parahydroxybenzoic acid.

26.

The process of Claim 25 wherein the ester of parahydroxybenzoic acid is a mixture of methyl and ethyl esters.

AMENDED CLAIMS

[received by the International Bureau on 27 February 1989 (27.02.89)
original claims 2 and 4 cancelled; new claim 25 added; other
claims unchanged (7 pages)]

1.

A free-flowing particulate
ibuprofen-containing granular composition capable of
being directly molded into a pharmaceutically
acceptable tablet having high hardness, short
5 disintegration time and fast dissolution rate
comprising:

- (a) from about 50 to about 85 percent,
based on the dry weight of the composition, of
ibuprofen;
- 10 (b) from about 1 to about 5 percent, based
on the dry weight of the composition, of an internally
cross-linked alkali carboxymethylcellulose;
- (c) a pharmaceutically acceptable lubricant
in an amount of at least sufficient to impart
15 effective mold release properties to the tablet;
- (d) cellulose and starch binders and
disintegrants; and
- (e) water therefor,
- 20 said composition having been prepared in a
fluidized bed granulator-dryer by process which
comprised spraying an aqueous dispersion of a starch
binder onto a fluidized powder comprising ibuprofen

and a portion of the said carboxymethylcellulose, drying the resulting granules to a moisture level of
25 from about 1 to about 5 percent based on the total weight of the composition; and thereafter blending a lubricant and the remaining portion of the said carboxymethylcellulose with the dry granules.

2.

A tablet shaped from the composition of Claim 1.

3.

The composition of Claim 1 wherein the blending is carried out using a double-cone blender.

4.

The composition of Claim 1 wherein the lubricant is stearic acid and comprises about 0.1 to 3.0 percent based on the dry weight of the composition.

5.

The composition of Claim 1 wherein the lubricant is calcium stearate and comprises about 0.1 to 3.0 percent based on the dry weight of the composition.

6.

The composition of Claim 5 wherein the aqueous spray contains a second pharmaceutically acceptable compressibility-promoting binder in an amount effective for further increasing the obtainable
5 hardness of tablets formed from such composition.

7.

The composition of Claim 6 wherein the second binder is providone.

8.

The composition of Claim 1 wherein the initially fluidized powder contains a second pharmaceutically acceptable compressibility-promoting binder in an amount effective for further increasing
5 the hardness of tablets formed from such composition.

9.

The composition of Claim 8 wherein the second binder is pregelatinized starch.

10.

A method of building free-flowing particulate ibuprofen-containing granules capable of being directly molded into a pharmaceutically acceptable tablet having high hardness, short disintegration time, and fast dissolution rate comprising:

- (a) fluidizing a finely divided powder of ibuprofen and an internally cross-linked alkali carboxymethylcellulose, each component having a particle size of about 15 to about 60 microns;
- (b) during the fluidization, spraying the fluidized powder with an aqueous dispersion of a pharmaceutically acceptable compressibility-promoting binder in an amount effective for increasing the obtainable hardness of tablets made from the resulting composition;
- (c) ceasing the spraying;
- (d) continuing the fluidization until the thus-built granules have a moisture content of about 2.0 to 5.0 weight percent water based on the total weight of the composition;
- (e) ceasing the fluidization; and
- (f) blending the dried granules with a pharmaceutically acceptable lubricant in an amount at least sufficient to impart effective mold release properties to tablets made from the resulting granules, and with additional carboxymethylcellulose whereby free-flowing granules having a particle size of about 140-225 microns are produced and being capable of being directly formed into pharmaceutically acceptable tablets.

24

11.

The process of Claim 10 wherein the blending is carried out using a double-cone blender.

12.

The process of Claim 10 wherein the lubricant is stearic acid and comprises about 0.1 to 3.0 percent based on the dry weight of the granules.

13.

The process of Claim 10 wherein the lubricant is calcium stearate and comprises about 0.1 to 3.0 percent based on the dry weight of the granules.

14.

The process of Claim 10 wherein the aqueous spray dispersion contains a second pharmaceutically acceptable compressibility-promoting binder in an amount effective for further increasing the obtainable hardness of tablets formed from the granules.

15.

The process of Claim 12 wherein the second binder is providone.

16.

The process of Claim 10 wherein both the initially fluidized powder contains a second pharmaceutically acceptable compressibility-promoting binder in an amount effective for increasing the hardness of tablets formed from the granules.

17.

The process of Claim 16 wherein the second binder is pregelatinized starch.

18.

The process of Claim 10 wherein a preservative is added during the spraying step in an amount sufficient to minimize microbial contamination of tablets made from the granules.

19.

The process of Claim 18 wherein the preservative is a lower alkyl ester of parahydroxybenzoic acid.

20.

The process of Claim 19 wherein the alkyl moiety of the preservative is C₁-C₅ alkyl.

21.

A method of building a free-flowing particulate ibuprofen-containing granules capable of being directly molded into a pharmaceutically acceptable tablet having high hardness, short
5 disintegration time, and fast dissolution rate comprising:

(a) fluidizing a dry finely divided powder of ibuprofen together with a pharmaceutically acceptable binder composed of a mixture of internally
10 cross-linked sodium carboxymethylcellulose, pregelatinized starch and microcrystalline cellulose, each ingredient of which having a particle size of about 15 to about 60 microns.

(b) during the fluidization, spraying the
15 fluidized powder with an aqueous dispersion containing a pharmaceutically acceptable binder composed of a mixture of pregelatinized starch and providone and a lower alkyl ester of parahydroxybenzoic acid as a pharmaceutically acceptable preservative;

20 (c) ceasing the spraying;

(d) continuing the fluidization until the intermediate built granules have a moisture content of about 2.0 to about 5.0 weight percent water based on the total weight of the composition;

25 (e) ceasing the fluidization;

(f) blending the intermediate built granules with a lubricant, additional internally

cross-linked sodium carboxymethylcellulose and microcrystalline cellulose as a mixture of binders;

(g) the binders present in the initially
30 fluidized powder and the aqueous dispersion and added during blending being present in an amount effective for increasing the obtainable hardness of tablets molded from the ultimate granules;

(h) the lubricant being present in an
35 amount sufficient to impart effective mold release properties to tablets molded from the ultimate granules;

(i) the preservative being present in an amount sufficient to minimize microbial contamination
40 of tablets molded from the ultimate granules;

whereby free-flowing granules having a particle size of about 140-225 microns are built and being capable of directly molded into pharmaceutically acceptable tablets with an ibuprofen dosage of about
45 100 to about 300 mg.

22.

The process of Claim 21 wherein the internally cross-linked sodium carboxymethylcellulose composes about 3 weight percent of the ultimate granules and having been incorporated in the initially
5 fluidized powder and in the composition added during blending in approximately equal amounts.

23.

The process of Claim 22, wherein the ultimate granules on a dry basis comprises about 63% ibuprofen, about 17% pregelatinized starch, about 15% microcrystalline cellulose, 3% internally cross-linked
5 sodium carboxymethylcellulose, about 1% lubricant, about 0.5% providone and about 0.1% lower alkyl ester of parahydroxybenzoic acid.

24.


The process of Claim 23 wherein the ester of parahydroxybenzoic acid is a mixture of methyl and ethyl esters.

25.

The composition of Claim 1 wherein the lubricant is a mixture of stearic acid and calcium stearate.

INTERNATIONAL SEARCH REPORT

International Application No PCT/US88/02945

| | | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|-------------------------------------|
| I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) * | | |
| According to International Patent Classification (IPC) or to both National Classification and IPC | | |
| IPC ⁴ : A 61 K 9/16, A 61 K 9/20; A 61 K 31/19 | | |
| II. FIELDS SEARCHED | | |
| Minimum Documentation Searched ? | | |
| Classification System | Classification Symbols | |
| IPC ⁴ | A 61 K | |
| Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched * | | |
| | | |
| III. DOCUMENTS CONSIDERED TO BE RELEVANT * | | |
| Category * | Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹² | Relevant to Claim No. ¹³ |
| Y | US, A, 4 609 675 (R M FRANTZ) 2 September 1986 claims -- | 1-4 |
| Y | US, A, 4 661 521 (A M SALPEKAR ET AL) 28 April 1987 column 2, lines 1-25, example 4, claims -- | 1-26 |
| Y | US, A, 4 439 453 (S H VOGEL) 27 March 1984 claims -- | 1-26 |
| Y | EP, A, 0 159 852 (MALLINCKRODT INC) 30 October 1985 whole document -- | 1-4 |
| Y | GB, A, 2 155 330 (E R SQUIBB & SONS INC.) 25 September 1985 page 1 lines 28-35, claims -- | 1-4 |
| <div style="display: flex; justify-content: space-between;"> <div style="width: 48%;"> <p>* Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 48%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div> | | |
| IV. CERTIFICATION | | |
| Date of the Actual Completion of the International Search | Date of Mailing of this International Search Report | |
| 2nd December 1988 | 28 DEC 1988 | |
| International Searching Authority | Signature of Authorized Officer | |
| EUROPEAN PATENT OFFICE |  P.C.G. VAN DER PUTTEN | |

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE PRECEDING SHEET)

| Category * | Citation of Document, with indication, where appropriate, of the relevant passages | Relevant to Claim No |
|------------|--------------------------------------------------------------------------------------------|----------------------|
| Y | GB, A, 1 390 032 (STERLING-WINTHROP GROUP LTD) 23 November 1972 whole document -- | 1-26 |
| P,A | EP, A, 0 240 351 (H LOWEY) 7 October 1987 claims 5, 11 ----- | 1-26 |

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

**PCT/US88/02945
SA 24274**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 02/11/88. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|-------------------------------------------|---------------------|-------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| US-A- 4609675 | 02-09-86 | EP-A- 0172014 JP-A-61057522 | 19-02-86 24-03-86 |
| US-A- 4661521 | 28-04-87 | US-A- 4757090 | 12-07-88 |
| US-A- 4439453 | 27-03-84 | BE-A- 891557 FR-A- 2496461 GB-A- 2090739 JP-A-57130913 DE-A- 3150557 CA-A- 1157776 AU-A- 545475 | 21-06-82 25-06-82 21-07-82 13-08-82 02-09-82 29-11-83 18-07-85 |
| EP-A- 0159852 | 30-10-85 | None | |
| GB-A- 2155330 | 25-09-85 | None | |
| GB-A- 1390032 | 09-04-75 | FR-A- 2150903 DE-A- 2241960 CA-A- 988424 | 13-04-73 15-03-73 04-05-76 |
| EP-A- 0240351 | 07-10-87 | JP-A-62294626 ZA-A- 8701818 US-A- 4775535 | 22-12-87 02-09-87 04-10-88 |